{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T14:40:34Z","timestamp":1789742434743,"version":"4.0.1"},"reference-count":61,"publisher":"American Diabetes Association","issue":"9","license":[{"start":{"date-parts":[[2021,6,27]],"date-time":"2021-06-27T00:00:00Z","timestamp":1624752000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.diabetesjournals.org\/content\/license"}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,9,1]]},"abstract":"<jats:p>Gastric inhibitory peptide (GIP) is best known for its role as an incretin hormone in control of blood glucose concentrations. As a classic satiation signal, however, the literature illustrates a mixed picture of GIP involvement with an at best weak anorectic response profile being reported for GIP receptor (GIPR) signaling. Not surprisingly, the pursuit of exploiting the GIP system as a therapeutic target for diabetes and obesity has fallen behind that of the other gastrointestinal-derived incretin, glucagon-like peptide 1 (GLP-1). However, recent discoveries highlighted here support potential therapeutic advantages of combinatorial therapies targeting GIP and GLP-1 systems together, with perhaps the most surprising finding that GIPR agonism may have antiemetic properties. As nausea and vomiting are the most common side effects of all existing GLP-1 pharmacotherapies, the ability for GIP agonism to reduce GLP-1\u2013induced illness behaviors but retain (if not enhance) weight loss and glycemic control may offer a new era in the treatment of obesity and diabetes.<\/jats:p>","DOI":"10.2337\/dbi21-0004","type":"journal-article","created":{"date-parts":[[2021,6,27]],"date-time":"2021-06-27T15:35:13Z","timestamp":1624808113000},"page":"1956-1961","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":64,"title":["The Role of GIP in the Regulation of GLP-1 Satiety and Nausea"],"prefix":"10.2337","volume":"70","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9782-6551","authenticated-orcid":false,"given":"Matthew R.","family":"Hayes","sequence":"first","affiliation":[{"name":"Department of Psychiatry, University of Pennsylvania, Philadelphia, PA"},{"name":"Department of Biobehavioral Health Sciences, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tito","family":"Borner","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, University of Pennsylvania, Philadelphia, PA"},{"name":"Department of Biobehavioral Health Sciences, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart C.","family":"De Jonghe","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, University of Pennsylvania, Philadelphia, PA"},{"name":"Department of Biobehavioral Health Sciences, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","published-online":{"date-parts":[[2021,6,27]]},"reference":[{"key":"2022031309280187900_B1","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1038\/sj.ijo.0801910","article-title":"Within-meal gut feedback signaling","volume":"25","author":"Moran","year":"2001","journal-title":"Int J Obes Relat Metab Disord"},{"key":"2022031309280187900_B2","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.cmet.2012.06.015","article-title":"Hindbrain neurons as an essential hub in the neuroanatomically distributed control of energy balance","volume":"16","author":"Grill","year":"2012","journal-title":"Cell Metab"},{"key":"2022031309280187900_B3","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1097\/00017285-200303000-00004","article-title":"The supersizing of America: portion size and the obesity epidemic","volume":"38","author":"Rolls","year":"2003","journal-title":"Nutr Today"},{"key":"2022031309280187900_B4","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1002\/eat.23509","article-title":"Intuitive eating and its psychological correlates: a meta-analysis","volume":"54","author":"Linardon","year":"2021","journal-title":"Int J Eat Disord"},{"key":"2022031309280187900_B5","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1038\/s41395-018-0039-2","article-title":"Chronic nausea and vomiting: evaluation and treatment","volume":"113","author":"Lacy","year":"2018","journal-title":"Am J Gastroenterol"},{"key":"2022031309280187900_B6","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1056\/NEJMra0706547","article-title":"Chemotherapy-induced nausea and vomiting","volume":"358","author":"Hesketh","year":"2008","journal-title":"N Engl J Med"},{"key":"2022031309280187900_B7","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1006\/frne.1994.1012","article-title":"The area postrema and vomiting","volume":"15","author":"Miller","year":"1994","journal-title":"Front Neuroendocrinol"},{"key":"2022031309280187900_B8","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ejphar.2013.08.047","article-title":"The role of vagal neurocircuits in the regulation of nausea and vomiting","volume":"722","author":"Babic","year":"2014","journal-title":"Eur J Pharmacol"},{"key":"2022031309280187900_B9","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1097\/00001610-200511000-00003","article-title":"The pathophysiology of chemotherapy-induced nausea and vomiting","volume":"28","author":"Baker","year":"2005","journal-title":"Gastroenterol Nurs"},{"key":"2022031309280187900_B10","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1007\/s00221-014-3985-y","article-title":"Measuring the nausea-to-emesis continuum in non-human animals: refocusing on gastrointestinal vagal signaling","volume":"232","author":"Horn","year":"2014","journal-title":"Exp Brain Res"},{"key":"2022031309280187900_B11","doi-asserted-by":"crossref","first-page":"4189","DOI":"10.1200\/JCO.2010.34.4614","article-title":"Antiemetics: American Society of Clinical Oncology clinical practice guideline update","volume":"29","author":"Basch","year":"2011","journal-title":"J Clin Oncol"},{"key":"2022031309280187900_B12","doi-asserted-by":"crossref","first-page":"403","DOI":"10.2147\/DMSO.S141235","article-title":"Reasons for discontinuation of GLP1 receptor agonists: data from a real-world cross-sectional survey of physicians and their patients with type 2 diabetes","volume":"10","author":"Sikirica","year":"2017","journal-title":"Diabetes Metab Syndr Obes"},{"key":"2022031309280187900_B13","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.autneu.2006.07.009","article-title":"Treatment of nausea and vomiting: gaps in our knowledge","volume":"129","author":"Sanger","year":"2006","journal-title":"Auton Neurosci"},{"key":"2022031309280187900_B14","doi-asserted-by":"crossref","first-page":"913","DOI":"10.3389\/fphar.2018.00913","article-title":"A history of drug discovery for treatment of nausea and vomiting and the implications for future research","volume":"9","author":"Sanger","year":"2018","journal-title":"Front Pharmacol"},{"key":"2022031309280187900_B15","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1053\/j.gastro.2007.03.054","article-title":"Biology of incretins: GLP-1 and GIP","volume":"132","author":"Baggio","year":"2007","journal-title":"Gastroenterology"},{"key":"2022031309280187900_B16","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1210\/jcem-37-5-826","article-title":"Stimulation of insulin secretion by gastric inhibitory polypeptide in man","volume":"37","author":"Dupre","year":"1973","journal-title":"J Clin Endocrinol Metab"},{"key":"2022031309280187900_B17","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1210\/edrv-16-3-390","article-title":"Cell and molecular biology of the incretin hormones glucagon-like peptide-I and glucose-dependent insulin releasing polypeptide","volume":"16","author":"Fehmann","year":"1995","journal-title":"Endocr Rev"},{"key":"2022031309280187900_B18","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.molmet.2019.09.010","article-title":"Glucagon-like peptide 1 (GLP-1)","volume":"30","author":"M\u00fcller","year":"2019","journal-title":"Mol Metab"},{"key":"2022031309280187900_B19","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.molmed.2016.03.005","article-title":"Reappraisal of GIP pharmacology for metabolic diseases","volume":"22","author":"Finan","year":"2016","journal-title":"Trends Mol Med"},{"key":"2022031309280187900_B20","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.tem.2020.02.006","article-title":"How may GIP enhance the therapeutic efficacy of GLP-1?","volume":"31","author":"Samms","year":"2020","journal-title":"Trends Endocrinol Metab"},{"key":"2022031309280187900_B21","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1172\/JCI116186","article-title":"Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus","volume":"91","author":"Nauck","year":"1993","journal-title":"J Clin Invest"},{"key":"2022031309280187900_B22","doi-asserted-by":"crossref","first-page":"E1746","DOI":"10.1152\/ajpendo.00460.2007","article-title":"GIP receptor antagonism reverses obesity, insulin resistance, and associated metabolic disturbances induced in mice by prolonged consumption of high-fat diet","volume":"293","author":"McClean","year":"2007","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"2022031309280187900_B23","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1038\/nm727","article-title":"Inhibition of gastric inhibitory polypeptide signaling prevents obesity","volume":"8","author":"Miyawaki","year":"2002","journal-title":"Nat Med"},{"key":"2022031309280187900_B24","doi-asserted-by":"crossref","first-page":"E1008","DOI":"10.1152\/ajpendo.00345.2015","article-title":"Gastric inhibitory polypeptide immunoneutralization attenuates development of obesity in mice","volume":"309","author":"Boylan","year":"2015","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"2022031309280187900_B25","doi-asserted-by":"crossref","first-page":"eaat3392","DOI":"10.1126\/scitranslmed.aat3392","article-title":"Anti-obesity effects of GIPR antagonists alone and in combination with GLP-1R agonists in preclinical models","volume":"10","author":"Killion","year":"2018","journal-title":"Sci Transl Med"},{"key":"2022031309280187900_B26","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.molmet.2018.12.001","article-title":"Optimized GIP analogs promote body weight lowering in mice through GIPR agonism not antagonism","volume":"20","author":"Mroz","year":"2019","journal-title":"Mol Metab"},{"key":"2022031309280187900_B27","doi-asserted-by":"crossref","first-page":"170201","DOI":"10.1016\/j.peptides.2019.170201","article-title":"Effects on pancreatic beta and other islet cells of the glucose-dependent insulinotropic polypeptide","volume":"125","author":"Khan","year":"2020","journal-title":"Peptides"},{"key":"2022031309280187900_B28","doi-asserted-by":"crossref","first-page":"170197","DOI":"10.1016\/j.peptides.2019.170197","article-title":"GIP and the gut-bone axis - physiological, pathophysiological and potential therapeutic implications","volume":"125","author":"Stensen","year":"2020","journal-title":"Peptides"},{"key":"2022031309280187900_B29","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.molmet.2019.08.006","article-title":"Physiological roles of the GIP receptor in murine brown adipose tissue","volume":"28","author":"Beaudry","year":"2019","journal-title":"Mol Metab"},{"key":"2022031309280187900_B30","doi-asserted-by":"crossref","first-page":"170208","DOI":"10.1016\/j.peptides.2019.170208","article-title":"The influence of glucose-dependent insulinotropic polypeptide (GIP) on human adipose tissue and fat metabolism: implications for obesity, type 2 diabetes and non-alcoholic fatty liver disease (NAFLD)","volume":"125","author":"Thondam","year":"2020","journal-title":"Peptides"},{"key":"2022031309280187900_B31","doi-asserted-by":"crossref","first-page":"eabf1948","DOI":"10.1126\/sciadv.abf1948","article-title":"GIP mediates the incretin effect and glucose tolerance by dual actions on \u03b1 cells and \u03b2 cells","volume":"7","author":"El","year":"2021","journal-title":"Sci Adv"},{"key":"2022031309280187900_B32","doi-asserted-by":"crossref","first-page":"7402","DOI":"10.1016\/S0021-9258(18)42531-8","article-title":"Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas","volume":"267","author":"Eng","year":"1992","journal-title":"J Biol Chem"},{"key":"2022031309280187900_B33","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1007\/s13300-020-00816-y","article-title":"Drug therapy in obesity: a review of current and emerging treatments","volume":"11","author":"Williams","year":"2020","journal-title":"Diabetes Ther"},{"key":"2022031309280187900_B34","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.2337\/dc13-2760","article-title":"Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1)","volume":"37","author":"Wysham","year":"2014","journal-title":"Diabetes Care"},{"key":"2022031309280187900_B35","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1111\/dom.13353","article-title":"Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline BMI or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials","volume":"20","author":"Ahr\u00e9n","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"2022031309280187900_B36","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S2213-8587(18)30024-X","article-title":"Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial","volume":"6","author":"Pratley","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2022031309280187900_B37","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1038\/npp.2016.246","article-title":"Endogenous glucagon-like peptide-1 receptor signaling in the nucleus tractus solitarius is Required for food intake control","volume":"42","author":"Alhadeff","year":"2017","journal-title":"Neuropsychopharmacology"},{"key":"2022031309280187900_B38","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.cmet.2011.02.001","article-title":"Intracellular signals mediating the food intake-suppressive effects of hindbrain glucagon-like peptide-1 receptor activation","volume":"13","author":"Hayes","year":"2011","journal-title":"Cell Metab"},{"key":"2022031309280187900_B39","doi-asserted-by":"crossref","first-page":"3103","DOI":"10.1210\/en.2011-0174","article-title":"Peripheral and central GLP-1 receptor populations mediate the anorectic effects of peripherally administered GLP-1 receptor agonists, liraglutide and exendin-4","volume":"152","author":"Kanoski","year":"2011","journal-title":"Endocrinology"},{"key":"2022031309280187900_B40","doi-asserted-by":"crossref","first-page":"E1367","DOI":"10.1152\/ajpendo.00413.2013","article-title":"The food intake-suppressive effects of glucagon-like peptide-1 receptor signaling in the ventral tegmental area are mediated by AMPA\/kainate receptors","volume":"305","author":"Mietlicki-Baase","year":"2013","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"2022031309280187900_B41","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1172\/JCI72434","article-title":"Neuronal GLP1R mediates liraglutide\u2019s anorectic but not glucose-lowering effect","volume":"124","author":"Sisley","year":"2014","journal-title":"J Clin Invest"},{"key":"2022031309280187900_B42","doi-asserted-by":"crossref","first-page":"4473","DOI":"10.1172\/JCI75276","article-title":"The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss","volume":"124","author":"Secher","year":"2014","journal-title":"J Clin Invest"},{"key":"2022031309280187900_B43","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1016\/j.neuropharm.2011.12.022","article-title":"The role of nausea in food intake and body weight suppression by peripheral GLP-1 receptor agonists, exendin-4 and liraglutide","volume":"62","author":"Kanoski","year":"2012","journal-title":"Neuropharmacology"},{"key":"2022031309280187900_B44","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1111\/dom.12824","article-title":"Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: a systematic analysis of published clinical trials","volume":"19","author":"Bettge","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"2022031309280187900_B45","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S0140-6736(18)31773-2","article-title":"Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial","volume":"392","author":"O\u2019Neil","year":"2018","journal-title":"Lancet"},{"key":"2022031309280187900_B46","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.diabet.2019.101117","article-title":"Efficacy and safety of once-weekly semaglutide 1.0mg vs once-daily liraglutide 1.2mg as add-on to 1-3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10)","volume":"46","author":"Capehorn","year":"2020","journal-title":"Diabetes Metab"},{"key":"2022031309280187900_B47","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/jcpt.13225","article-title":"Safety and tolerability of once-weekly GLP-1 receptor agonists in type 2 diabetes","volume":"45","author":"Trujillo","year":"2020","journal-title":"J Clin Pharm Ther"},{"key":"2022031309280187900_B48","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S0140-6736(10)60590-9","article-title":"Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial","volume":"376","author":"Bergenstal","year":"2010","journal-title":"Lancet"},{"key":"2022031309280187900_B49","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.2337\/diacare.27.11.2628","article-title":"Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes","volume":"27","author":"Buse","year":"2004","journal-title":"Diabetes Care"},{"key":"2022031309280187900_B50","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.2337\/diacare.28.5.1092","article-title":"Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes","volume":"28","author":"DeFronzo","year":"2005","journal-title":"Diabetes Care"},{"key":"2022031309280187900_B51","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.2337\/diacare.28.5.1083","article-title":"Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea","volume":"28","author":"Kendall","year":"2005","journal-title":"Diabetes Care"},{"key":"2022031309280187900_B52","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2337\/diaspect.20.1.59","article-title":"Expanded use of exenatide in the management of type 2 diabetes","volume":"20","author":"John","year":"2007","journal-title":"Diabetes Spectr"},{"key":"2022031309280187900_B53","article-title":"GIP receptor activating peptide","author":"Asami"},{"key":"2022031309280187900_B54","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.molmet.2018.09.009","article-title":"LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept","volume":"18","author":"Coskun","year":"2018","journal-title":"Mol Metab"},{"key":"2022031309280187900_B55","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/dom.13034","article-title":"A novel GIP analogue, ZP4165, enhances glucagon-like peptide-1-induced body weight loss and improves glycaemic control in rodents","volume":"20","author":"N\u00f8rregaard","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"2022031309280187900_B56","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.cmet.2017.07.011","article-title":"The sustained effects of a dual GIP\/GLP-1 receptor agonist, NNC0090-2746, in patients with type 2 diabetes","volume":"26","author":"Frias","year":"2017","journal-title":"Cell Metab"},{"key":"2022031309280187900_B57","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1016\/S0140-6736(18)32260-8","article-title":"Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial","volume":"392","author":"Frias","year":"2018","journal-title":"Lancet"},{"key":"2022031309280187900_B58","doi-asserted-by":"crossref","first-page":"209ra151","DOI":"10.1126\/scitranslmed.3007218","article-title":"Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans","volume":"5","author":"Finan","year":"2013","journal-title":"Sci Transl Med"},{"key":"2022031309280187900_B59","doi-asserted-by":"crossref","unstructured":"Geisler\u2008C, Borner\u2008T, Gaisinsky\u2008J, et al. GIP receptor agonism attenuates GLP-1 receptor agonist induced nausea in rodents, 2020. Accessed 5 November 2020. Available from https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/oby.23063","DOI":"10.2337\/figshare.15125112.v1"},{"key":"2022031309280187900_B60","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.neuron.2020.11.010","article-title":"Area postrema cell types that mediate nausea-associated behaviors","volume":"109","author":"Zhang","year":"2021","journal-title":"Neuron"},{"key":"2022031309280187900_B61","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/s42255-021-00363-1","article-title":"A genetic map of the mouse dorsal vagal complex and its role in obesity","volume":"3","author":"Ludwig","year":"2021","journal-title":"Nat Metab"}],"container-title":["Diabetes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.org\/diabetes\/diabetes\/article-pdf\/70\/9\/1956\/627744\/dbi210004.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/diabetes\/article-pdf\/70\/9\/1956\/627744\/dbi210004.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,2]],"date-time":"2022-11-02T16:42:30Z","timestamp":1667407350000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/diabetes\/article\/70\/9\/1956\/137765\/The-Role-of-GIP-in-the-Regulation-of-GLP-1-Satiety"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,27]]},"references-count":61,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2021,6,27]]},"published-print":{"date-parts":[[2021,9,1]]}},"URL":"https:\/\/doi.org\/10.2337\/dbi21-0004","relation":{},"ISSN":["0012-1797","1939-327X"],"issn-type":[{"value":"0012-1797","type":"print"},{"value":"1939-327X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,27]]}}}